Five-year outcomes in liver transplant patients receiving everolimus with or without a calcineurin inhibitor: Results from the CERTITUDE study.
Faouzi SalibaChristophe DuvouxSébastien DharancyJérôme DumortierYvon CalmusJean GugenheimNassim KamarEphrem SalaméMartine Neau-CransacClaire VanlemmensFrançois DurandGeorges Philippe PageauxJean HardwigsenYasmina BenkhatarFrançois DerquenneFilomena ContiPublished in: Liver international : official journal of the International Association for the Study of the Liver (2022)
The CERTITUDE study demonstrated that EVR- and TAC-based regimens have comparable efficacy, safety and tolerability up to 5 years post-LTx.